FDA Approves Lilly's Tirzepatide to Cut Heart Risks in Type 2 Diabetes
The U. S. Food and Drug Administration has approved Eli Lilly's tirzepatide for a new indication: reducing major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. The approval covers cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Tirzepatide is a GIP/GLP-1 receptor agonist.
The U. S. Food and Drug Administration (FDA) has approved a new indication for tirzepatide, allowing its use to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus (T2DM) who are at high risk for cardiovascular events. MACE includes cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Tirzepatide is a GIP/GLP-1 receptor agonist. Eli Lilly and Company announced the approval decision recently.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 70/100 and 80% confidence over a medium term horizon.
Pharmaceuticals
- Direction
- positive
- Intensity
- 70
- Confidence
- 80%
- Horizon
- Medium term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 50
- Confidence
- 70%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.